The purposes of this study is :~to improve characterization of symptomatic FTD patients or presymptomatic subjects at risk of genetic FTD~to develop markers indicative of the optimal time to start disease-modifying therapy, based on the proximity to clinical onset.~to develop markers of disease progression that can be used as outcome measures.~to derive sample size estimates for clinical trials.~Participants will include those affected with the disorder as well as at-risk members of families (both mutation carriers and non-carrier first-degree relatives who will serve as a control group).~All participants will be assessed longitudinally with a set of clinical, neuropsychiatric, cognitive, imaging and biosample protocols.
GENFI Lille is a French cohort that belongs to the international initiative GENFI2, a five year longitudinal biomarker cohort study of genetic FTD and its associated disorders (including MND/ALS) investigating members of families with a known mutation in GRN or MAPT or an expansion in C9orf72 (including those affected with the disorder as well as at-risk members of families).